Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyAjay K. Nooka, Niels W.C.J. van de Donk, Cesar Rodriguez et al.|Cancer|2023Cited by 87
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Sundar Jagannath, Keqin Qi et al.|eJHaem|2021Cited by 31
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Kwee Yong, Thomas G. Martin et al.|Clinical Drug Investigation|2021Cited by 23
Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).Thomas Martin, Sundar Jagannath, Amrita Krishnan et al.|Journal of Clinical Oncology|2021Cited by 7
MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 StudySalomon Manier, Niels W.C.J. van de Donk, Ajay K. Nooka et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 2